Mutations Associated With Parkinson s Disease
| Status: | Terminated |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 8/31/2018 |
| Start Date: | February 27, 2012 |
| End Date: | August 27, 2018 |
Metabolic Phenotyping of Subjects With Mutations Associated With Hereditary Parkinson's Disease
Background:
- Early-onset Parkinson's disease (EOPD) is more likely to be caused by gene mutations than
Parkinson's disease that develops in older people. Studying these mutations may help find
therapies for EOPD. Researchers want to study mutations on a gene called PARK2. These
mutations prevent fat uptake into cells and may interfere with normal brain function.
Researchers want to study fat and cholesterol in the body to look at the effects of these
mutations on the body and brain.
Objectives:
- To study connections between genetic mutations and EOPD.
Eligibility:
- Individuals between 18 and 80 years of age with EOPD.
- Individuals between 18 and 80 years of age with no family history of Parkinson s
disease.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will also be collected.
- Participants will have some or all of the following tests:
- Blood samples and tissue (skin and fat) biopsies
- Cell line development from these tissue samples to study the function of PARK2
- DEXA scan to measure body fat context using low dose x-rays
- Glucose and insulin tolerance testing to measure blood sugar levels.
- Treatment will not be provided as part of this protocol.
- Early-onset Parkinson's disease (EOPD) is more likely to be caused by gene mutations than
Parkinson's disease that develops in older people. Studying these mutations may help find
therapies for EOPD. Researchers want to study mutations on a gene called PARK2. These
mutations prevent fat uptake into cells and may interfere with normal brain function.
Researchers want to study fat and cholesterol in the body to look at the effects of these
mutations on the body and brain.
Objectives:
- To study connections between genetic mutations and EOPD.
Eligibility:
- Individuals between 18 and 80 years of age with EOPD.
- Individuals between 18 and 80 years of age with no family history of Parkinson s
disease.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will also be collected.
- Participants will have some or all of the following tests:
- Blood samples and tissue (skin and fat) biopsies
- Cell line development from these tissue samples to study the function of PARK2
- DEXA scan to measure body fat context using low dose x-rays
- Glucose and insulin tolerance testing to measure blood sugar levels.
- Treatment will not be provided as part of this protocol.
The majority of subjects with the degenerative Parkinson s Disease present at around the age
of 70 years. Other subjects develop this brain disease before the age of 40 years. This early
onset presentation is more likely to have a direct genetic cause than the degenerative form
of the disease. Our understanding of the genetic causes of early onset Parkinson s Disease
may help us find therapies for both the genetic and more degenerative illnesses. Our
laboratory has found that one of the genetic mutations associated with early onset Parkinson
s Disease, in a gene called PARK2 results in impaired uptake of fat into cells. This may have
detrimental effects in the brain, as the brain requires fat to make cholesterol and to send
brain signals. A finding in mice lacking PARK2, is that they are resistant to diet induced
diabetes and obesity and to fatty liver. These data suggests that the systemic and brain
effects of low fat uptake may be opposing, with low fat uptake having a beneficial effect
against risk factors such as obesity and diabetes but increasing the risk for brain diseases.
To begin to test whether this is the case in subjects with PARK2 mutations we propose to test
their fat uptake and glucose and insulin sensitivity.
of 70 years. Other subjects develop this brain disease before the age of 40 years. This early
onset presentation is more likely to have a direct genetic cause than the degenerative form
of the disease. Our understanding of the genetic causes of early onset Parkinson s Disease
may help us find therapies for both the genetic and more degenerative illnesses. Our
laboratory has found that one of the genetic mutations associated with early onset Parkinson
s Disease, in a gene called PARK2 results in impaired uptake of fat into cells. This may have
detrimental effects in the brain, as the brain requires fat to make cholesterol and to send
brain signals. A finding in mice lacking PARK2, is that they are resistant to diet induced
diabetes and obesity and to fatty liver. These data suggests that the systemic and brain
effects of low fat uptake may be opposing, with low fat uptake having a beneficial effect
against risk factors such as obesity and diabetes but increasing the risk for brain diseases.
To begin to test whether this is the case in subjects with PARK2 mutations we propose to test
their fat uptake and glucose and insulin sensitivity.
- INCLUSION CRITERIA:
Parkinson s Subjects:
Screening:
- Age 18 years to 80 years old with a history of early onset Parkinson disease
(Presentation within the first five decades of life).
- Diagnosis of Parkinson disease or Parkinsonism
- Willingness and legal ability to give and sign informed study consent
Enrollment:
- Mutations in PARK2
- Willingness to travel to NIH for scheduled protocol studies
Control Subjects:
- Age 18 years to 80 years old with no history or family history of Parkinson disease.
- Willingness and legal ability to give and sign informed study consent
- Willingness to travel to NIH for scheduled protocol studies
- Willingness to have blood or tissue samples studied, and potentially stored for future
research
EXCLUSION CRITERIA:
Parkinson Subjects:
Screening:
- Subjects who are unable or unwilling to sign an informed consent subjects with genetic
defects associated with other diseases including other neurologic syndromes.
- Subjects without medically treated diabetes who are unable/unwilling to undergo a
glucose tolerance test
Enrollment:
- Pregnancy
Control Subjects
- Subjects who are unable or unwilling to sign an informed consent
- Subjects with genetic defects associated with other diseases including other
neurologic syndromes.
- Pregnancy
- Medically treated diabetes
- Unable/unwilling to undergo a glucose tolerance test
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
